White House drops Heidi Overton's nomination for FDA commissioner
by Margaret Brennan, Ed O'Keefe · CBS NEWSThe White House has dropped the nomination of Dr. Heidi Overton, President Trump's pick for Food and Drug Administration commissioner, according to a senior administration official and other people familiar with the decision.
The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on Overton's nomination Wednesday.
Axios was first to report that Overton was dropped.
Overton had struggled to shore up support among Senate Republicans, CBS News had previously reported. Some lawmakers and administration allies had expressed skepticism of Overton, partly due to her testimony regarding the FDA-approved abortion drug mifepristone and her execution of Mr. Trump's pro-vape policies.
Republican Sen. Bill Cassidy of Louisiana, the outgoing chair of the Senate HELP Committee, argued late Tuesday the issue was not that Overton lacked the votes to get confirmed. He said the "White House abandoned a viable confirmation path."
Cassidy wrote in a statement that "pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues," but the Trump administration withdrew Overton instead.
"I believe she would have had the votes to pass out of committee and pass the full Senate. My conversations with her convinced me she would follow the science and push back against decisions that put Americans' health at risk," he said.
Two sources familiar with the matter said the White House shared its decision to withdraw Overton's nomination Tuesday evening. At the time, whip efforts were still underway to garner enough Republican votes to advance Overton.
Mr. Trump nominated Overton — a physician and White House domestic policy staffer — to the FDA role over the summer. The agency, which regulates products that account for about 20% of U.S. consumer spending, has not had a Senate-confirmed leader since Dr. Marty Makary was forced out in May.
Overton was seen as close to former White House chief of staff Susie Wiles, who departed her role earlier this month.
Prior to the decision to withdraw Overton, the White House had begun talking to other potential candidates for FDA chief, including some who could serve in an acting capacity and thus forgo Senate confirmation, a source told CBS News earlier Tuesday. The agency is currently run by acting Commissioner Kyle Diamantas.
Two sources indicated Sen. Roger Marshall of Kansas, a doctor, is making a play for the FDA post. He lost his reelection bid to Democrat Adam Hamilton earlier this month.
Any Senate-confirmed FDA commissioner would need to be confirmed during a narrow window before Democrats take control of the chamber in January.
Cassidy told CBS News on Tuesday that "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."
In an interview with "Face the Nation with Margaret Brennan" on Sunday, Cassidy expressed concern that an acting FDA administer would have less independence than a Senate-confirmed leader.
"The question is, do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody's mind, but at least would be a permanent one and have the ability to establish some independence?" he said.